XV Konferencja Naukowa Polskiego Towarzystwa Hepatologicznego
Current issue
Archival Issues
Manuscript Submission
Journal Abstract
Managing cytopenia associated with anti-HCV therapy
Dorota Kozielewicz, Dorota Dybowska
Medical Science Review - Hepatologia 2009; 9 51-53
aaICID: 902242
Article type: Review article
IC™ Value: 3.04
Abstract provided by Publisher
The recommended therapy for chronic hepatitis C is the combination of pegylated interferon alpha and ribavirin. The optimal drug doses have a direct influence on achieving a sustain virologic response (SVR). This therapy is associated with several adverse events, such as hematological side effects. The most frequent adverse effect is anemia, followed neutro- and thrombocytopenia. Using hematological growth factors allows the administration of a full course of the antiviral drugs and thereby achievement of a higher rate of SVR.

ICID 902242

Related articles
  • in IndexCopernicus™
         Neutropenia [72 related records]
         Thrombocytopenia [124 related records]
         Anemia [234 related records]
         HCV infection [11 related records]
         pegylated [0 related records]
         interferon [24 related records]
         ribavirin [49 related records]


    Copyright © Medical Science Review - Hepatologia  2019
    Page created by Index Copernicus Ltd. All Rights reserved.